Investigational VEGF antagonists for psoriasis

Bibliography

• Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803
   PubMed Web of Science ®Google Scholar
• Brenchley PEC. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 2000;121:426-9
   PubMed Web of Science ®Google Scholar
• Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1:703-18
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Claffey KP, Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
   PubMed Web of Science ®Google Scholar
• Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007;16:83-107
   PubMed Web of Science ®Google Scholar
• Canavese M, Altruda F, Ruzicka T, Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis–a possible target for novel therapies? J Dermatol Sci 2010;58:171-6
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Clauss M, Gerlach M, Gerlach H, Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45
   PubMed Web of Science ®Google Scholar
• Bhushan M, McLaughlin B, Weiss JB, Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-60
   PubMed Web of Science ®Google Scholar
• Young HS, Summers AM, Bhushan M, Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004;122:209-15
   PubMed Web of Science ®Google Scholar
• Young HS, Summers AM, Read IR, Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006;126:453-9
   PubMed Web of Science ®Google Scholar
• Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43
   PubMedGoogle Scholar
• Winder T, Lenz HJ. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 2010;138:2163-76
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72
   PubMed Web of Science ®Google Scholar
• Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011;22:199-204
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker JNWN. Psoriasis. N Engl J Med 2009;361:496-509
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 1972;59:40-3
   PubMed Web of Science ®Google Scholar
• Xia YP, Li B, Hylton D, Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8
   PubMed Web of Science ®Google Scholar
• Halin C, Fahrngruber H, Meingassner JG, Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008;173:265-77
   PubMed Web of Science ®Google Scholar
• Schonthaler HB, Huggenberger R, Wculek SK, Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proceedings of the National Academy of Sciences of the United States of America; 2009. p. 21264-9
   Google Scholar
• Jung K, Lee D, Lim HS, Double Anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-{alpha} in retinopathy and psoriasis. J Biol Chem 2011;286:14410-18
   PubMed Web of Science ®Google Scholar
• Kunstfeld R, Hirakawa S, Hong YK, Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004;104:1048-57
   PubMed Web of Science ®Google Scholar
• Akman A, Yilmaz E, Mutlu H, Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 2009;34:e202-4
   PubMed Web of Science ®Google Scholar
• Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007;149:103-6
   PubMed Web of Science ®Google Scholar
• Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J 2010;16:17
   PubMedGoogle Scholar
• Narayanan S, Callis-Duffin K, Batten J, Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 2010;339:580-1
   PubMed Web of Science ®Google Scholar
• Flisiak I, Zaniewski P, Rogalska-Taranta M, Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. J Eur Acad Dermatol Venereol 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Akman A, Dicle O, Yilmaz F, Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed 2008;24:123-7
   PubMed Web of Science ®Google Scholar
• Hernandez GL, Volpert OV, Iniguez MA, Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001;193:607-20
   PubMed Web of Science ®Google Scholar
• Meissner M, Doll M, Hrgovic I, Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol 2011;131:1356-64
   PubMed Web of Science ®Google Scholar
• Markham T, Mullan R, Golden-Mason L, Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006;54:1003-12
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, Kraan MC, Picavet DI, Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6:R326-34
   PubMed Web of Science ®Google Scholar
• Creamer D, Allen M, Jaggar R, Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002;138:791-6
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Schon MP, Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6
   PubMed Web of Science ®Google Scholar
• Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 1982;33:214-17
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974;109:207-11
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-46
   PubMed Web of Science ®Google Scholar
• Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64:37-9
   Web of Science ®Google Scholar
• Strange A, Capon F, Spencer CC, A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-90
   PubMed Web of Science ®Google Scholar
• Trembath RC, Clough RL, Rosbotham JL, Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813-20
   PubMed Web of Science ®Google Scholar
• Brogan IJ, Khan N, Isaac K, Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999;60:1245-9
   PubMed Web of Science ®Google Scholar
• Watson CJ, Webb NJ, Bottomley MJ, Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-5
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Storkebaum E, Morimoto M, VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94
   PubMed Web of Science ®Google Scholar
• Diaz F, Bourguignon LY. Selective down-regulation of IP(3)receptor subtypes by caspases and calpain during TNF alpha -induced apoptosis of human T-lymphoma cells. Cell Calcium 2000;27:315-28
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Luttun A, Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83
   PubMed Web of Science ®Google Scholar
• Young HS, Janes L, Plant D, Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) in inflammatory skin disease. 4th International Congress The Royal College of Physicians; London, UK; 2005. p. 154
   Google Scholar
• Fisher LB, Maibach HI. The effect of anthralin and its derivatives on epidermal cell kinetics. J Invest Dermatol 1975;64:338-41
   PubMed Web of Science ®Google Scholar
• Andrys C, Borska L, Pohl D, Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007;298:479-83
   PubMed Web of Science ®Google Scholar
• Deng H, Yan CL, Hu Y, Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. Photodermatol Photoimmunol Photomed 2004;20:191-9
   PubMed Web of Science ®Google Scholar
• Yano K, Kadoya K, Kajiya K, Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 2005;152:115-21
   PubMed Web of Science ®Google Scholar
• Arbiser JL. Fumarate esters as angiogenesis inhibitors: key to action in psoriasis? J Invest Dermatol 2011;131:1189-91
   PubMed Web of Science ®Google Scholar
• Garcia-Caballero M, Mari-Beffa M, Medina MA, Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect? J Invest Dermatol 2011;131:1347-55
   PubMed Web of Science ®Google Scholar
• Giraudo E, Primo L, Audero E, Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998;273:22128-35
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12:356-61
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-18
   PubMed Web of Science ®Google Scholar
• Cohen MH, Shen YL, Keegan P, FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-8
   PubMed Web of Science ®Google Scholar
• Summers J, Cohen MH, Keegan P, FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010;15:104-11
   PubMed Web of Science ®Google Scholar
• Geiger-Gritsch S, Stollenwerk B, Miksad R, Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010;15:1179-91
   PubMed Web of Science ®Google Scholar
• Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol 2008;181:131-50
   PubMedGoogle Scholar
• O'Connor JP, Carano RA, Clamp AR, Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-82
   PubMed Web of Science ®Google Scholar
• Zenz R, Eferl R, Kenner L, Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Leighl NB, Raez LE, Besse B, A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010;5:1054-9
   PubMed Web of Science ®Google Scholar
• FDA Panel Recommends Approval of Aflibercept for Wet AMD. 20/06/2011 Available from: http://www.medscape.com/viewarticle/744920 [Last accessed 23 July 2011]
   Google Scholar
• Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2011. [Epub ahead of print]
   Google Scholar
• Twardowski P, Stadler WM, Frankel P, Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California cancer Consortium trial. Urology 2010;76:923-6
   PubMed Web of Science ®Google Scholar
• de Groot JF, Lamborn KR, Chang SM, Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol 2011;29:2689-95
   PubMed Web of Science ®Google Scholar
• Witte L, Hicklin DJ, Zhu Z, Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17:155-61
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 2011;71:1179-91
   PubMed Web of Science ®Google Scholar
• Rock EP, Goodman V, Jiang JX, Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-13
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet 2007;370:272-84
   PubMed Web of Science ®Google Scholar
• Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-53
   PubMed Web of Science ®Google Scholar
• Adnane L, Trail PA, Taylor I, Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612
   PubMed Web of Science ®Google Scholar
• Hutson TE, Bellmunt J, Porta C, Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III target. Eur J Cancer 2010;46:2432-40
   PubMed Web of Science ®Google Scholar
• Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008 134:379
   Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• Fuh G, Wu P, Liang WC, Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006;281:6625-31
   PubMed Web of Science ®Google Scholar